Literature DB >> 12744852

The use of hepatitis a vaccination in Italy: an economic evaluation.

Vittorio Demicheli1, Emanuela Carniglia, Stefania Fucci.   

Abstract

We report on the conduct and results of an economic model of two different strategies of vaccination against hepatitis A in Italy. In strategy 1 (universal vaccination), all newborns are vaccinated simultaneously with MMR at 15 months and all 12 year olds are vaccinated with combined hepatitis A and B vaccine. In strategy 2 (contacts' vaccination) only subjects with a close social and spatial relationship with the sick are vaccinated. In strategy 1 costs per avoided case and net costs per avoided case values are always very high. Net costs become very low when newborns and 12 year olds are vaccinated, and become negative (indicating a potential gain) when 12 year olds are vaccinated. From an economic viewpoint, universal vaccination appears recommendable only in epidemic conditions. For strategy 2 our model shows that cost for avoidable case are very low and net costs for avoided case are always negative, showing the potential presence of an absolute benefit. We conclude that in Italy mass vaccination appears economically worthwhile only during epidemics but vaccination of contacts is an economically worthwhile routine measure.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12744852     DOI: 10.1016/s0264-410x(03)00136-1

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis.

Authors:  Eduardo Lopez; Roberto Debbag; Laurent Coudeville; Florence Baron-Papillon; Judith Armoni
Journal:  J Gastroenterol       Date:  2007-03-12       Impact factor: 7.527

Review 2.  Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Authors:  Andrea M Anonychuk; Andrea C Tricco; Chris T Bauch; Ba' Pham; Vladimir Gilca; Bernard Duval; Ava John-Baptiste; Gloria Woo; Murray Krahn
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

3.  Economic consequences of the vaccination against hepatitis A in the Bulgarian healthcare setting.

Authors:  Maria Dimitrova; Guenka Petrova; Konstantin Tachkov; Maria Krasteva Bozhkova; Maria Kamusheva; Konstantin Mitov
Journal:  Biotechnol Biotechnol Equip       Date:  2014-07-10       Impact factor: 1.632

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.